Applied DNA Sciences Inc (APDN): Price and Financial Metrics


Applied DNA Sciences Inc (APDN)

Today's Latest Price: $7.18 USD

0.45 (6.69%)

Updated Nov 27 1:00pm

Add APDN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 369 in Miscellaneous

See all "A" rated Strong Buy stocks

APDN Stock Summary

  • APDN has a higher market value than only 11.51% of US stocks; more precisely, its current market capitalization is $36,925,153.
  • Revenue growth over the past 12 months for Applied Dna Sciences Inc comes in at -33.01%, a number that bests merely 10.17% of the US stocks we're tracking.
  • Applied Dna Sciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -55.3%, greater than the shareholder yield of only 6.61% of stocks in our set.
  • Stocks that are quantitatively similar to APDN, based on their financial statements, market capitalization, and price volatility, are ICAD, NBRV, OBLN, AUTO, and HTGM.
  • Visit APDN's SEC page to see the company's official filings. To visit the company's web site, go to www.adnas.com.

APDN Stock Price Chart Interactive Chart >

Price chart for APDN

APDN Price/Volume Stats

Current price $7.18 52-week high $16.39
Prev. close $6.73 52-week low $2.52
Day low $6.60 Volume 271,700
Day high $7.23 Avg. volume 1,074,044
50-day MA $7.41 Dividend yield N/A
200-day MA $7.40 Market Cap 36.93M

APDN Latest News Stream


Event/Time News Detail
Loading, please wait...

APDN Latest Social Stream


Loading social stream, please wait...

View Full APDN Social Stream

Latest APDN News From Around the Web

Below are the latest news stories about Applied Dna Sciences Inc that investors may wish to consider to help them evaluate APDN as an investment opportunity.

Applied DNA Sciences +2% PM on new supply deal for its CertainT platform

Applied DNA Sciences (APDN) enters into supply agreement with ITW Pillar Technologies to deploy its CertainT platform used to tag products with a unique molecular identifier.Under the agreement, Applied DNA will incorporate SigNature molecular tags into textiles, including those used in personal protective equipment, that are treated with Pillar’s patented plasma deposition...

Seeking Alpha | September 21, 2020

Applied DNA/Takis Bio to launch veterinary study of Linear COVID-19 vaccine candidate

Applied DNA Sciences (APDN) jumps 13% premarket in reaction to announcement that the company and Evvivax, S.R.L., a spin-out of Takis Biotech are expected to initiate a veterinary clinical trial of one of the Company’s five LineaDNA vaccine candidates.The goal of the trial is to evaluate the vaccine candidate for the prevention...

Seeking Alpha | September 16, 2020

Applied DNA to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 15

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced that Dr. James A. Hayward, Chief Executive Officer, will participate virtually in the H.C Wainwright 22nd Annual Global Investment Confer

Business Wire | September 2, 2020

Applied DNA Provides Update on Status of New York State Laboratory Permit for Clinical Labs Subsidiary

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), announced that the Company’s wholly owned diagnostics testing subsidiary, Applied DNA Clinical Labs, LLC (“ADCL”), has completed all compliance and clinical data submissions required under the Clinical Laboratory Evaluation Program (CLEP) administered by the New York State Department of Health’s (DoH) Wadsworth Center to secure a clinical laboratory permit to conduct COVID-19 testing.

Business Wire | August 27, 2020

Applied DNA Reports Fiscal Third Quarter 2020 Financial Results

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced consolidated financial results for the fiscal third quarter and the nine months ended June 30, 2020. “We continued during the quarter to

Business Wire | August 6, 2020

Read More 'APDN' Stories Here

APDN Price Returns

1-mo -6.87%
3-mo -2.05%
6-mo -25.52%
1-year 71.77%
3-year -92.33%
5-year -94.11%
YTD 71.36%
2019 -73.81%
2018 -74.84%
2017 -14.05%
2016 -42.90%
2015 12.11%

Continue Researching APDN

Want to see what other sources are saying about Applied Dna Sciences Inc's financials and stock price? Try the links below:

Applied Dna Sciences Inc (APDN) Stock Price | Nasdaq
Applied Dna Sciences Inc (APDN) Stock Quote, History and News - Yahoo Finance
Applied Dna Sciences Inc (APDN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8791 seconds.